Data published in The Lancet Oncology support high efficacy previously demonstrated by Cervarix®(HPV 16 and 18 vaccine) against precancerous cervical lesions caused by HPV 16 …

Abstract:

An analysis published today in TheLancet Oncology reinforces previous findings showing that GlaxoSmithKline’s Cervarix®, provided protection against advanced precancerous lesions (CIN3+), above that expected from a vaccine that protects against human papillomavirus (HPV) types 16 and 18. CIN3+ is the immediate step before invasive cervical cancer and data showing protection against this type of lesion are considered the most stringent evidence of potential cervical cancer prevention. 1 Results from the largest efficacy trial of a cervical cancer vaccine to date (PATRICIA), show that Cervarix provided 93%† efficacy against CIN3+ irrespective of the HPV type associated with the CIN3+ lesion. 1 This pre-defined, exploratory analysis was conducted in women with no evidence of past or current HPV infection.‡ These women are thought to be representative of young girls prior to the onset of sexual activity–the …

Año de publicación:

Keywords:

Fuente:

google